Subgroup Analysis from a Phase 1/2 Randomized Clinical Trial of 2.6% EDTA Ophthalmic Solution in Patients with Age-Related Cataract.
Tatsuya KuboiRoy S ChuckRoberto PinedaRajiv BhushanAmit GoswamyRandall J Olson
Published in: American journal of ophthalmology (2024)
A significant treatment effect of C-KAD in visual function and vision quality was observed consistently. These promising results suggest a novel, noninvasive pharmacological treatment to improve vision in patients with early-stage cataract.